<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1">

Our Products

TriviumVet is addressing serious conditions in pets for whom there is no direct treatment and/or for which current treatments do not deliver satisfactory results. Read on to learn about the breakthrough solutions we are developing to help raise the standard of care for dogs and cats in several key areas.

Felycin®-CA1

Felycin®-CA1

Felycin®-CA1 (sirolimus delayed release tablets), administered once weekly, is indicated for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). 

This is the first Conditionally Approved drug for the treatment of Feline HCM.

Liavium

Liavium-CA1

Liavium-CA1 (pregabalin chewable tablets) - Analgesic for oral use in dogs only.

Indicated for the control of pain and clinical signs associated with Chiari-Like Malformation and Syringomyelia in dogs.

30mg, 90mg, 180mg tablets (90mg tablets are SCORED) - US Market launch coming soon.

TriviumVet Pill Template With Shadow And Padding

Zetbelis

Coming soon to the European market.

 

Vet taking information with pet owner and cat

Take Part In Our Clinical Studies

TriviumVet is dedicated to raising the standard of treatment for some of the most serious medical conditions in pets. This requires quality clinical research, and for that we need your help. There are several different ways you can be part of our research driving therapeutic advances to enhance the lives of pets and the people who love them.

Having a pet with a serious health problem is frightening. Participating in a study that is investigating a promising new therapy can not only provide hope for your pet, but it may also allow you and your pet to be part of research that brings hope to many more pets and owners. 

View Our Clinical Studiesbutton-arrow-right